Shares slid 3.8% to $247.52 this morning after AbbVie delivered a strong Q2 beat but simultaneously trimmed its full-year profit outlook to absorb the cost of its biggest acquisition in half a decade. AbbVie trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping second-quarter estimates on strong immunology drug sales. The result is a tug-of-war between today's operational strength and tomorrow's deal-driven earnings drag.
The Quarter Was Clean — Two Blockbuster Drugs Keep Delivering. Skyrizi hit $4.48 billion in Q1 2026 (up 30.9% year-over-year) and Rinvoq added $2.12 billion (up 23.3%). Those two drugs, which treat autoimmune conditions like psoriasis and arthritis, have decisively replaced Humira as AbbVie's growth engine. Q2 EPS was expected to go up 67% year-over-year , and management had guided revenue of roughly $16.7 billion. The market was expecting AbbVie's revenue to grow 8.8% year on year. The beat confirms the core business is humming.
The Guidance Cut Is Small, but the Clock Is Long. In an 8-K filed July 6, AbbVie said acquired research-and-development expenses of $291 million in Q2 would reduce earnings by $0.17 per share, revising full-year adjusted EPS guidance to $13.91–$14.11 — well below the $14.25 consensus. The $10.9 billion all-cash Apogee purchase cuts adjusted EPS by $0.14 in 2026 and $0.46 in 2027 before turning accretive — meaning it adds to profits rather than subtracts — in 2032. That is six years of dilution shareholders must underwrite.
The Apogee Bet Is About Survival After the Next Patent Cliff. The acquisition underscores the surge in pharmaceutical dealmaking as companies race to build portfolios ahead of looming patent expirations. AbbVie has pursued M&A to build new growth drivers as it prepares for patent cliffs on Skyrizi and Rinvoq. Apogee's lead experimental drug targets eczema and asthma, and cross-trial comparisons suggest it can match or improve on rival treatments from Lilly, Sanofi, and Regeneron while reducing injection burden. If approved, it extends AbbVie's franchise; if not, $10.9 billion evaporates.
Wall Street Was Already Priced for Good News. The stock had rallied from $256.91 to $263.30 in the days before earnings. ABBV traded at a forward price-to-earnings ratio of 18x with a PEG of 0.43 , leaving little room for a guidance cut. Some caution around the Apogee transaction comes from analysts where the $10.9 billion price is seen as full and the deal timing raises questions over execution risk. Today's sell-off erased roughly $17 billion in market value — the market's way of demanding proof that the Apogee payoff will arrive on schedule.